Bookbuilding IPO | ₹48 Cr | Listed at NSE SME | Wed, May 17, 2023 - Fri, May 19, 2023
Remus Pharmaceuticals IPO is a book build issue of ₹47.69 crores. The issue is entirely a fresh issue of 0.04 crore shares of ₹47.69 crore.
Remus Pharmaceuticals IPO bidding started from May 17, 2023 and ended on May 19, 2023. The allotment for Remus Pharmaceuticals IPO was finalized on May 24, 2023. The shares got listed on NSE SME on May 29, 2023.
Remus Pharmaceuticals IPO price band is set at ₹1,229 per share. The lot size for an application is 100. The minimum amount of investment required by an retail is ₹1,22,900 (100 shares) (based on upper price). The minimum lot size for investment in HNI is 2 lots (200 shares), amounting to ₹2,45,800.
Beeline Capital Advisors Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Sunflower Broking Pvt.Ltd..
Refer to Remus Pharmaceuticals IPO RHP for detailed Information.
IPO Open
Wed, May 17, 2023
IPO Close
Fri, May 19, 2023
Issue Price
₹1229 per share
Market Cap (Pre-IPO)
₹181.03 Cr
| IPO Date | 17 to 19 May, 2023 |
| Listed on | Mon, May 29, 2023 |
| Face Value | ₹10 per share |
| Price Band | ₹1150 to ₹1229 |
| Issue Price | ₹1229 per share |
| Lot Size | 100 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 3,88,000 shares (agg. up to ₹48 Cr) |
| Reserved for Market Maker | 19,500 shares Sunflower Broking Pvt.Ltd. (agg. up to ₹2 Cr) |
| Fresh Issue (Ex Market Maker) | 3,68,500 shares (agg. up to ₹45 Cr) |
| Net Offered to Public | 3,68,500 shares (agg. up to ₹45 Cr) |
| Share Holding Pre Issue | 10,85,000 shares |
| Share Holding Post Issue | 14,73,000 shares |
| NSE Symbol | REMUS |
| ISIN | INE0O5T01011 |
Remus Pharmaceuticals IPO comprises a total issue size of 3,88,000 shares. The net offer to the public is 3,68,500 shares, after excluding 19,500 shares allotted on a firm basis. Of the Net offer 1,84,200 (49.99%) are allocated to QIB, 55,300 (15.01%) allocated to NII 1,29,000 (35.01%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 1,84,200 | 49.99% | 47.47% |
| − Anchor Investor Shares Offered | 1,10,500 | 28.48% | |
| − QIB (Ex. Anchor) Shares Offered | 73,700 | 18.99% | |
| NII (HNI) Shares Offered | 55,300 | 15.01% | 14.25% |
| Retail Shares Offered | 1,29,000 | 35.01% | 33.25% |
| Firm Reservations | |||
| Market Maker Shares Offered | 19,500 | 5.03% | |
| Total Shares Offered | 3,88,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 100 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 100 | ₹1,22,900 |
| Retail (Max) | 1 | 100 | ₹1,22,900 |
| HNI (Min) | 2 | 200 | ₹2,45,800 |
Remus Pharmaceuticals IPO raises ₹13.58 crore from anchor investors. Remus Pharmaceuticals IPO Anchor bid date is May 16, 2023.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, May 16, 2023 |
| Shares Offered | 1,10,500 |
| Anchor Portion (₹ Cr.) | 13.58 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Jun 23, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Aug 22, 2023 |
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.
As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.
| Period Ended | 31 Dec 2022 | 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 |
|---|---|---|---|---|
| Assets | 33.53 | 15.91 | 11.05 | 5.30 |
| Total Income | 33.61 | 25.44 | 19.22 | 12.77 |
| Profit After Tax | 6.44 | 3.39 | 1.03 | 0.81 |
| NET Worth | 17.12 | 6.43 | 3.05 | 2.02 |
| Reserves and Surplus | 16.04 | 5.43 | 3.04 | 2.01 |
| Total Borrowing | 9.47 | 0.19 | 0.28 | 0.36 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To Meet Working Capital Requirements | 30.30 |
| 2 | Funding investments for acquisitions and general corporate purposes | 16.38 |
| 3 | Public Issue Expenses | 1.00 |
| KPI | |
|---|---|
| ROE | 71.44% |
| ROCE | 69.99% |
| Debt/Equity | 0.03 |
| RoNW | 52.64% |
| PAT Margin | 13.70% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 33.86 | |
| P/E (x) | 21.09 | |
| Promoter Holding | 92.82% | 68.37% |
| Market Cap | ₹181.03 Cr. |
The Remus Pharmaceuticals IPO is subscribed 57.21 times on May 19, 2023 7:29:00 PM (Day 3). The public issue subscribed 49.81 times in the retail category, 10.75 times in the QIB category, and 229.31 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 10.75 | 1,38,750 | 14,92,000 |
| NII* | 229.31 | 41,625 | 95,45,000 |
| Retail | 49.81 | 97,125 | 48,37,600 |
| Total | 57.21 | 2,77,500 | 1,58,74,600 |
Total Application : 48,376
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Manger Fees including Underwriting Commission | 0.73 |
| 2 | Fees Payable to Registrar to the Issue | 0.02 |
| 3 | Fees Payable Advertising, Marketing Expenses and Printing Expenses | 0.08 |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | 0.07 |
| 5 | Fees payable to Peer Review Auditor | 0.02 |
| 6 | Fees Payable to Market Maker (for Two Years) | 0.08 |
| 7 | Escrow Bank Fees | 0.01 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹1,229.00 |
| Open | ₹1,711.25 |
| Low | ₹1,711.25 |
| High | ₹1,796.80 |
| Last Trade | ₹1,796.80 |
Lead Manager Reports
Remus Pharmaceuticals IPO is a SME IPO of 3,88,000 equity shares of the face value of ₹10 aggregating up to ₹48 Crores. The issue is priced at ₹1229 per share. The minimum order quantity is 100.
The IPO opens on Wed, May 17, 2023, and closes on Fri, May 19, 2023.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Remus Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Remus Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Remus Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Remus Pharmaceuticals IPO opens on Wed, May 17, 2023 and closes on Fri, May 19, 2023.
Remus Pharmaceuticals IPO lot size is 100, and the minimum amount required for application is ₹1,22,900.
You can apply in Remus Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Remus Pharmaceuticals IPO will be done on Wednesday, May 24, 2023, and the allotted shares will be credited to your demat account by Fri, May 26, 2023. Check the Remus Pharmaceuticals IPO allotment status.
The Remus Pharmaceuticals IPO listing date is on Mon, May 29, 2023.
